R01CA249981

MUTOGRAPHS DIFFERENTIATING THE RACIAL AND TEMPORAL INCIDENCE OF MULTIPLE MYELOMA - PROJECT SUMMARY/ABSTRACT

African Americans (AA) have a higher incidence of multiple myeloma (MM) compared to European Americans (EA) due to genetic predisposition, environmental exposure, or both. MM is preceded by two precursor phases, monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM), which are also increased in AA.

We have shown, using European MM samples, that there is a long lag period between the genetic initiation of the disease and the time at which precursor clinical stages are detectable. It is critical to understand the genetic basis of these early evolutionary steps if we are to truly understand the excess risk of MM in AA.

During the evolutionary progression of MM after genetic initiation, genetic hits are accumulated, providing a unique archaeological fingerprint of the mutational signatures or "mutographs" over time. Using whole genome sequencing (WGS) analyzed with advanced computer algorithms based on a priori knowledge of the timing of acquired genetic variants, we have been able to extract mutographs active at different time points. This analysis has shown in EA that MM is shaped by mutational processes variably active during the early, intermediate, and late evolutionary phases of the disease.

A key finding of our pilot data is the identification of a mutograph occurring as a consequence of the immune response in the germinal center reaction, and this differs by race. We will address the hypothesis that a major contributor to the observed excess of MM in AA compared to EA is due to an excess immune response that can be recognized by a GC mutograph that is active in the early evolutionary phases of the disease.

To accurately extract early mutographs, sequential samples from the same individual cases are needed. SMM, which transforms to MM at a rate of 10% per annum, provides a system where samples can be obtained at different time points in the absence of treatment. To address our hypothesis, we will generate mutographs from new WGS data from AA SMM and compare them to existing datasets of EA with SMM, as well as from a large pre-existing set of MM from which we will infer ancestry directly.

We will also establish a longitudinal cohort study of SMM cases and study mutographs over time and compare the profiles between AA and EA. In addition to genetic mutographs, we will characterize and compare immunological mutographs of T-cell response in the bone marrow immune microenvironment identified using a flow-cytometric approach.

To provide a link to the external environment, we will characterize bacterial species signatures derived from 16S rRNA sequencing of the gut flora and link findings to the genetic and T-cell mutographs.

This study will identify genomic, immune, and environmental signatures responsible for the higher risk of MM observed among AAs and will provide new insights into the immune response in MM pathogenesis, opening the way for the generation of effective intervention strategies.

New York University

NOT APPLICABLE

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

New York, New York 100165818 United States

Single Zip Code

Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial Optional) (PAR-19-279)

Amendment Since initial award the total obligations have increased 260% from $1,234,790 to $4,448,534.